New Delhi, June 21:
Alembic Pharmaceuticals has received the US health regulator’s approval to market hypertension drug, Candesartan Cilexetil tablets, in the American market.
The company’s product is therapeutically equivalent to AstraZeneca Pharmaceuticals’ Atacand tablets which are indicated for treatment of hypertension, Alembic today said in a regulatory filing.
According to IMS data, Candesartan Cilexetil tablets had an estimated market size of $27 million in the US market for the 12 months ended December 2016.
Alembic now has a total of 57 abbreviated new drug application (ANDA) approvals from the USFDA.
Shares of the company today closed 2.28 per cent higher at Rs 534.90 on the BSE.
(This article was published on June 21, 2017)
Get more of your favourite news delivered to your inbox
Please enter your email. Thank You.
Newsletter has been successfully subscribed.